Nanobiotix S.A. (NBTX) 10-Year Financial Performance & Capital Metrics

NBTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutNanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.Show more

Revenue -$12M -132.1%
EBITDA -$67M -154.6%
Net Income -$68M -71.6%
EPS (Diluted) -1.44 -33.3%
Gross Margin 100%
EBITDA Margin 575.17% +894.0%
Operating Margin 589.13% +896.6%
Net Margin 586.89% +635.3%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -8.46 -152.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 175.7% free cash flow margin
✓Momentum leader: RS Rating 97 (top 3%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 28.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM655.62%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM16.33%

EPS CAGR

10Y-

5Y-

3Y-

TTM36.3%

ROCE

10Y Avg-99.28%

5Y Avg-110.88%

3Y Avg-149.83%

Latest-260.51%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	265.54K	1.56M	251.97K	116K	68K	50K	2.65M	4.78M	36.21M	-11.61M
Revenue Growth %	-0.73%	4.87%	-0.84%	-0.54%	-0.41%	-0.26%	51.94%	0.8%	6.58%	-1.32%
Cost of Goods Sold+	359.61K	436.31K	345.59K	0	0	0	0	985K	0	0
COGS % of Revenue	1.35%	0.28%	1.37%	-	-	-	-	0.21%	-	-
Gross Profit+	-94.07K	1.12M	-93.62K	116K	68K	50K	2.65M	3.79M	36.21M	-11.61M
Gross Margin %	-0.35%	0.72%	-0.37%	1%	1%	1%	1%	0.79%	1%	1%
Gross Profit Growth %	-1.1%	12.93%	-1.08%	2.24%	-0.41%	-0.26%	51.94%	0.43%	8.55%	-1.32%
Operating Expenses+	17.41M	23.41M	25.52M	30.18M	46.85M	38.75M	55.23M	51.48M	62.99M	56.78M
OpEx % of Revenue	65.55%	15.03%	101.28%	260.21%	688.93%	775.06%	20.86%	10.78%	1.74%	-4.89%
Selling, General & Admin	7.19M	10.26M	12.34M	12.62M	18.64M	14.27M	19.43M	17.48M	22.05M	20.06M
SG&A % of Revenue	27.07%	6.58%	48.96%	108.78%	274.12%	285.42%	7.34%	3.66%	0.61%	-1.73%
Research & Development	13.9M	16.92M	16.34M	20.89M	30.41M	24.33M	30.38M	32.64M	38.4M	40.54M
R&D % of Revenue	52.35%	10.86%	64.84%	180.11%	447.22%	486.6%	11.48%	6.83%	1.06%	-3.49%
Other Operating Expenses	0	160.23K	-337.89K	-3.33M	-2.2M	152K	5.41M	1.36M	2.54M	-3.82M
Operating Income+	-17.14M	-21.85M	-25.27M	-30.07M	-46.78M	-36.43M	-52.58M	-46.7M	-26.78M	-68.39M
Operating Margin %	-64.55%	-14.03%	-100.28%	-259.2%	-687.93%	-728.56%	-19.86%	-9.78%	-0.74%	5.89%
Operating Income Growth %	-0.78%	-0.27%	-0.16%	-0.19%	-0.56%	0.22%	-0.44%	0.11%	0.43%	-1.55%
EBITDA+	-16.69M	-21.42M	-24.92M	-29.5M	-45.01M	-34.67M	-51.02M	-45.2M	-26.23M	-66.77M
EBITDA Margin %	-62.84%	-13.75%	-98.91%	-254.29%	-661.9%	-693.46%	-19.27%	-9.46%	-0.72%	5.75%
EBITDA Growth %	-0.79%	-0.28%	-0.16%	-0.18%	-0.53%	0.23%	-0.47%	0.11%	0.42%	-1.55%
D&A (Non-Cash Add-back)	456.08K	436.31K	345.59K	569K	1.77M	1.75M	1.56M	1.5M	551K	1.62M
EBIT	-16.94M	-21.69M	-26.04M	-29.5M	-46.12M	-33.25M	-47.16M	-45.72M	-24.24M	-59.95M
Net Interest Income+	160.5K	130.29K	-60K	-726K	-4.55M	-333K	-658K	-5.58M	-6.76M	-5.46M
Interest Income	183.22K	59.49K	33.03K	34K	105K	0	6.17M	256K	1.22M	2.63M
Interest Expense	59.52K	102.2K	108.37K	847K	4.79M	333K	671K	5.84M	7.98M	8.09M
Other Income/Expense	138.56K	64.61K	-876K	-278K	-4.13M	2.85M	5.58M	-10.33M	-12.8M	361K
Pretax Income+	-17M	-21.79M	-26.14M	-30.34M	-50.91M	-33.61M	-47M	-57.03M	-39.58M	-68.03M
Pretax Margin %	-64.03%	-13.99%	-103.76%	-261.59%	-748.69%	-672.28%	-17.76%	-11.94%	-1.09%	5.86%
Income Tax+	37.58K	90.42K	20	-449K	3K	9K	5K	10K	120K	101K
Effective Tax Rate %	1%	1%	1%	0.99%	1%	1%	1%	1%	1%	1%
Net Income+	-17M	-21.88M	-26.14M	-29.9M	-50.91M	-33.62M	-47M	-57.04M	-39.7M	-68.13M
Net Margin %	-64.03%	-14.04%	-103.76%	-257.72%	-748.75%	-672.46%	-17.76%	-11.94%	-1.1%	5.87%
Net Income Growth %	-0.78%	-0.29%	-0.19%	-0.14%	-0.7%	0.34%	-0.4%	-0.21%	0.3%	-0.72%
Net Income (Continuing)	-17M	-21.88M	-26.14M	-30.34M	-50.91M	-33.59M	-47M	-57.04M	-39.7M	-68.13M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.20	-1.43	-1.50	-1.52	-2.35	-1.38	-1.35	-1.64	-1.08	-1.44
EPS Growth %	-0.62%	-0.19%	-0.05%	-0.01%	-0.55%	0.41%	0.02%	-0.21%	0.34%	-0.33%
EPS (Basic)	-1.20	-1.43	-1.50	-1.52	-2.35	-1.38	-1.35	-1.64	-1.08	-1.44
Diluted Shares Outstanding	14.14M	15.28M	17.48M	19.63M	21.63M	24.39M	34.73M	34.85M	36.93M	47.27M
Basic Shares Outstanding	14.14M	15.28M	17.43M	19.62M	21.63M	24.39M	34.73M	34.85M	36.76M	47.27M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	22.95M	26.89M	53.11M	42.65M	46.13M	125.25M	93.06M	52.36M	87.34M	61.47M
Cash & Short-Term Investments	17M	21.06M	47.21M	36.2M	35.09M	119.15M	83.92M	41.39M	75.28M	49.74M
Cash Only	17M	21.06M	47.21M	36.2M	35.09M	119.15M	83.92M	41.39M	75.28M	49.74M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	707.38K	5.21K	844K	997K	1.26M	3.88M	6.93M	2.84M	2.97M	8.54M
Days Sales Outstanding	972.32	1.22	1.22K	3.14K	6.74K	28.32K	955.04	217.2	29.91	-268.35
Inventory	1.21M	-5.03M	-4.9M	1.09M	2.67M	0	-3.04M	2.98M	200K	0
Days Inventory Outstanding	1.23K	-	-	-	-	-	-	1.1K	-	-
Other Current Assets	4.66M	5.02M	4.73M	5.33M	4.43M	0	3.04M	2.17M	6.33M	-1K
Total Non-Current Assets+	3.47M	3.51M	4.36M	3.54M	10.08M	8.78M	8.71M	7.41M	6.56M	5.95M
Property, Plant & Equipment	2.43M	2.43M	2.99M	2.88M	9.39M	8.26M	8.19M	7.12M	6.11M	5.54M
Fixed Asset Turnover	0.11x	0.64x	0.08x	0.04x	0.01x	0.01x	0.32x	0.67x	5.93x	-2.10x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	7.53K	4.45K	135.97K	102K	163K	21K	4K	1K	8K	7K
Long-Term Investments	218.12K	242.22K	272.93K	176K	131K	105K	98K	0	0	0
Other Non-Current Assets	0	0	0	382K	-1K	-1K	421K	291K	443K	406K
Total Assets+	26.42M	30.4M	57.47M	46.2M	56.2M	134.03M	101.77M	59.77M	93.9M	67.42M
Asset Turnover	0.01x	0.05x	0.00x	0.00x	0.00x	0.00x	0.03x	0.08x	0.39x	-0.17x
Asset Growth %	-0.29%	0.15%	0.89%	-0.2%	0.22%	1.38%	-0.24%	-0.41%	0.57%	-0.28%
Total Current Liabilities+	7.1M	8.25M	9.35M	11.6M	14.35M	19.04M	36.84M	37.94M	49.87M	58.94M
Accounts Payable	3.59M	4.37M	5.14M	4.54M	6.15M	5.57M	5M	4M	6.7M	4.48M
Days Payables Outstanding	3.64K	3.66K	5.43K	-	-	-	-	1.48K	-	-
Short-Term Debt	1.07M	1.08M	770K	500K	500K	3.67M	7.08M	3.6M	3.82M	3.66M
Deferred Revenue (Current)	1000K	1000K	1000K	93K	1000K	0	1000K	1000K	0	1000K
Other Current Liabilities	-790.5K	556.3K	807.47K	567K	-6.7M	7.06M	5.39M	7.41M	19.86M	8.27M
Current Ratio	3.23x	3.26x	5.68x	3.68x	3.22x	6.58x	2.53x	1.38x	1.75x	1.04x
Quick Ratio	3.06x	3.87x	6.20x	3.58x	3.03x	6.58x	2.61x	1.30x	1.75x	1.04x
Cash Conversion Cycle	-1.44K	-	-	-	-	-	-	-160.03	-	-
Total Non-Current Liabilities+	3.7M	4.76M	4.19M	20.36M	43.77M	44.52M	38.13M	48.88M	45.87M	74.19M
Long-Term Debt	3.53M	4.58M	3.75M	20.02M	37.62M	39.12M	32.42M	44.04M	41.66M	43.01M
Capital Lease Obligations	0	0	0	0	5.81M	4.99M	5.39M	4.57M	3.88M	2.97M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	173.91K	175.21K	446.27K	334K	332K	414K	318K	270K	325K	28.21M
Total Liabilities	10.81M	13M	13.54M	31.95M	58.11M	63.56M	74.98M	86.81M	95.74M	133.12M
Total Debt+	4.6M	5.67M	4.73M	20.52M	44.53M	48.98M	46.02M	53.17M	50.56M	50.9M
Net Debt	-12.4M	-15.39M	-42.48M	-15.68M	9.43M	-70.17M	-37.9M	11.78M	-24.72M	1.17M
Debt / Equity	0.29x	0.33x	0.11x	1.44x	-	0.70x	1.72x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-288.01x	-213.84x	-233.16x	-35.50x	-9.76x	-109.39x	-78.36x	-8.00x	-3.35x	-8.46x
Total Equity+	15.61M	17.4M	43.92M	14.24M	-1.91M	70.47M	26.79M	-27.05M	-1.84M	-65.7M
Equity Growth %	-0.49%	0.11%	1.52%	-0.68%	-1.13%	37.91%	-0.62%	-2.01%	0.93%	-34.63%
Book Value per Share	1.10	1.14	2.51	0.73	-0.09	2.89	0.77	-0.78	-0.05	-1.39
Total Shareholders' Equity	15.61M	17.4M	43.92M	14.24M	-1.91M	70.47M	26.79M	-27.05M	-1.84M	-65.7M
Common Stock	424.97K	478.96K	589K	589K	672K	1.03M	1.04M	1.05M	1.41M	1.42M
Retained Earnings	-17M	-21.88M	-26.14M	-30.34M	-50.91M	-33.59M	-47M	-57.04M	-39.7M	-68.13M
Treasury Stock	-81.88K	-57.77K	-27K	-124K	-169K	-196K	-202K	-228K	-228K	-228K
Accumulated OCI	-20.36M	-35.44M	-54.28M	-78.68M	-104.64M	-152.51M	-182.82M	-226.58M	-276.07M	-311.51M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-16.82M	-18.28M	-21.03M	-25.98M	-41.17M	-27.54M	-29.87M	-37.1M	-12.48M	-19.55M
Operating CF Margin %	-63.34%	-11.73%	-83.47%	-224.01%	-605.43%	-550.76%	-11.29%	-7.77%	-0.34%	1.68%
Operating CF Growth %	-0.96%	-0.09%	-0.15%	-0.24%	-0.58%	0.33%	-0.08%	-0.24%	0.66%	-0.57%
Net Income	-17M	-21.88M	-26.14M	-30.34M	-50.91M	-33.59M	-47M	-57.04M	-39.7M	-68.13M
Depreciation & Amortization	456.08K	482.79K	403.85K	619K	1.77M	1.75M	1.56M	1.5M	1.51M	1.62M
Stock-Based Compensation	1.29M	1.99M	2.61M	1.87M	4.32M	2.92M	3.2M	3.17M	3.3M	4.3M
Deferred Taxes	0	0	0	0	2.1M	5.64M	152K	0	120K	101K
Other Non-Cash Items	8.56K	-75.17K	430.32K	796K	3.08M	-4.34M	678K	12.96M	12.37M	28.28M
Working Capital Changes	-1.57M	1.2M	1.67M	1.08M	-1.52M	73K	11.54M	2.3M	9.92M	14.28M
Change in Receivables	-78.39K	74.82K	-164.29K	144K	-85K	-51K	62K	-101K	-806K	355K
Change in Inventory	0	0	0	0	-2.06M	995K	281K	-2.91M	0	0
Change in Payables	1.35M	788.69K	785.95K	633K	2.06M	-995K	-281K	2.91M	8.68M	0
Cash from Investing+	-2.21M	-444.99K	-1.46M	71K	-1.46M	-112K	-242K	138K	-349K	-955K
Capital Expenditures	-1.49M	-400.1K	-1.46M	-506K	-1.44M	-107K	-233K	-93K	-328K	-846K
CapEx % of Revenue	5.63%	0.26%	5.81%	4.36%	21.24%	2.14%	0.09%	0.02%	0.01%	-0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	72.95K	-44.88K	-224K	577K	1K	-1K	0	0	-21K	-109K
Cash from Financing+	3.06M	22.9M	48.53M	14.85M	41.49M	111.77M	-5.18M	-5.65M	46.77M	-5.13M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	417K	-1.43M	-3.56M	-223K	-461K	-11.05M	-1.44M	-916K	-9.77M	-980K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-18.32M	-18.68M	-22.5M	-26.49M	-42.61M	-27.64M	-30.11M	-37.2M	-12.81M	-20.4M
FCF Margin %	-68.97%	-11.99%	-89.29%	-228.37%	-626.66%	-552.9%	-11.37%	-7.79%	-0.35%	1.76%
FCF Growth %	-0.92%	-0.02%	-0.2%	-0.18%	-0.61%	0.35%	-0.09%	-0.24%	0.66%	-0.59%
FCF per Share	-1.30	-1.22	-1.29	-1.35	-1.97	-1.13	-0.87	-1.07	-0.35	-0.43
FCF Conversion (FCF/Net Income)	0.99x	0.84x	0.80x	0.87x	0.81x	0.82x	0.64x	0.65x	0.31x	0.29x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-74.04%	-132.57%	-85.27%	-102.8%	-825.6%	-98.08%	-96.66%	-	-	-
Return on Invested Capital (ROIC)	-898.73%	-628.39%	-1099.69%	-	-1153.33%	-698.84%	-	-	-	-
Gross Margin	-35.42%	72%	-37.16%	100%	100%	100%	100%	79.38%	100%	100%
Net Margin	-6403.14%	-1404.31%	-10375.62%	-25772.41%	-74875%	-67246%	-1775.75%	-1194.37%	-109.64%	586.89%
Debt / Equity	0.29x	0.33x	0.11x	1.44x	-	0.70x	1.72x	-	-	-
Interest Coverage	-288.01x	-213.84x	-233.16x	-35.50x	-9.76x	-109.39x	-78.36x	-8.00x	-3.35x	-8.46x
FCF Conversion	0.99x	0.84x	0.80x	0.87x	0.81x	0.82x	0.64x	0.65x	0.31x	0.29x
Revenue Growth	-72.55%	486.76%	-83.83%	-53.96%	-41.38%	-26.47%	5194%	80.43%	658.12%	-132.06%

Revenue by Segment

	2020	2021	2023	2024
Other Sales	-	5K	-	5.92M
Other Sales Growth	-	-	-	-
Services	50K	5K	29.75M	-17.53M
Services Growth	-	-90.00%	594900.00%	-158.94%

Frequently Asked Questions

Growth & Financials

Nanobiotix S.A. (NBTX) reported $47.9M in revenue for fiscal year 2024. This represents a 3424% increase from $1.4M in 2011.

Nanobiotix S.A. (NBTX) saw revenue decline by 132.1% over the past year.

Nanobiotix S.A. (NBTX) reported a net loss of $85.1M for fiscal year 2024.

Dividend & Returns

Nanobiotix S.A. (NBTX) had negative free cash flow of $33.2M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Nanobiotix S.A. (NBTX) 10-Year Financial Performance & Capital Metrics

NBTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue -$12M -132.1%
EBITDA -$67M -154.6%
Net Income -$68M -71.6%
EPS (Diluted) -1.44 -33.3%
Gross Margin 100%
EBITDA Margin 575.17% +894.0%
Operating Margin 589.13% +896.6%
Net Margin 586.89% +635.3%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -8.46 -152.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 175.7% free cash flow margin
✓Momentum leader: RS Rating 97 (top 3%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 28.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM655.62%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM16.33%

EPS CAGR

10Y-

5Y-

3Y-

TTM36.3%

ROCE

10Y Avg-99.28%

5Y Avg-110.88%

3Y Avg-149.83%

Latest-260.51%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	265.54K	1.56M	251.97K	116K	68K	50K	2.65M	4.78M	36.21M	-11.61M
Revenue Growth %	-0.73%	4.87%	-0.84%	-0.54%	-0.41%	-0.26%	51.94%	0.8%	6.58%	-1.32%
Cost of Goods Sold+	359.61K	436.31K	345.59K	0	0	0	0	985K	0	0
COGS % of Revenue	1.35%	0.28%	1.37%	-	-	-	-	0.21%	-	-
Gross Profit+	-94.07K	1.12M	-93.62K	116K	68K	50K	2.65M	3.79M	36.21M	-11.61M
Gross Margin %	-0.35%	0.72%	-0.37%	1%	1%	1%	1%	0.79%	1%	1%
Gross Profit Growth %	-1.1%	12.93%	-1.08%	2.24%	-0.41%	-0.26%	51.94%	0.43%	8.55%	-1.32%
Operating Expenses+	17.41M	23.41M	25.52M	30.18M	46.85M	38.75M	55.23M	51.48M	62.99M	56.78M
OpEx % of Revenue	65.55%	15.03%	101.28%	260.21%	688.93%	775.06%	20.86%	10.78%	1.74%	-4.89%
Selling, General & Admin	7.19M	10.26M	12.34M	12.62M	18.64M	14.27M	19.43M	17.48M	22.05M	20.06M
SG&A % of Revenue	27.07%	6.58%	48.96%	108.78%	274.12%	285.42%	7.34%	3.66%	0.61%	-1.73%
Research & Development	13.9M	16.92M	16.34M	20.89M	30.41M	24.33M	30.38M	32.64M	38.4M	40.54M
R&D % of Revenue	52.35%	10.86%	64.84%	180.11%	447.22%	486.6%	11.48%	6.83%	1.06%	-3.49%
Other Operating Expenses	0	160.23K	-337.89K	-3.33M	-2.2M	152K	5.41M	1.36M	2.54M	-3.82M
Operating Income+	-17.14M	-21.85M	-25.27M	-30.07M	-46.78M	-36.43M	-52.58M	-46.7M	-26.78M	-68.39M
Operating Margin %	-64.55%	-14.03%	-100.28%	-259.2%	-687.93%	-728.56%	-19.86%	-9.78%	-0.74%	5.89%
Operating Income Growth %	-0.78%	-0.27%	-0.16%	-0.19%	-0.56%	0.22%	-0.44%	0.11%	0.43%	-1.55%
EBITDA+	-16.69M	-21.42M	-24.92M	-29.5M	-45.01M	-34.67M	-51.02M	-45.2M	-26.23M	-66.77M
EBITDA Margin %	-62.84%	-13.75%	-98.91%	-254.29%	-661.9%	-693.46%	-19.27%	-9.46%	-0.72%	5.75%
EBITDA Growth %	-0.79%	-0.28%	-0.16%	-0.18%	-0.53%	0.23%	-0.47%	0.11%	0.42%	-1.55%
D&A (Non-Cash Add-back)	456.08K	436.31K	345.59K	569K	1.77M	1.75M	1.56M	1.5M	551K	1.62M
EBIT	-16.94M	-21.69M	-26.04M	-29.5M	-46.12M	-33.25M	-47.16M	-45.72M	-24.24M	-59.95M
Net Interest Income+	160.5K	130.29K	-60K	-726K	-4.55M	-333K	-658K	-5.58M	-6.76M	-5.46M
Interest Income	183.22K	59.49K	33.03K	34K	105K	0	6.17M	256K	1.22M	2.63M
Interest Expense	59.52K	102.2K	108.37K	847K	4.79M	333K	671K	5.84M	7.98M	8.09M
Other Income/Expense	138.56K	64.61K	-876K	-278K	-4.13M	2.85M	5.58M	-10.33M	-12.8M	361K
Pretax Income+	-17M	-21.79M	-26.14M	-30.34M	-50.91M	-33.61M	-47M	-57.03M	-39.58M	-68.03M
Pretax Margin %	-64.03%	-13.99%	-103.76%	-261.59%	-748.69%	-672.28%	-17.76%	-11.94%	-1.09%	5.86%
Income Tax+	37.58K	90.42K	20	-449K	3K	9K	5K	10K	120K	101K
Effective Tax Rate %	1%	1%	1%	0.99%	1%	1%	1%	1%	1%	1%
Net Income+	-17M	-21.88M	-26.14M	-29.9M	-50.91M	-33.62M	-47M	-57.04M	-39.7M	-68.13M
Net Margin %	-64.03%	-14.04%	-103.76%	-257.72%	-748.75%	-672.46%	-17.76%	-11.94%	-1.1%	5.87%
Net Income Growth %	-0.78%	-0.29%	-0.19%	-0.14%	-0.7%	0.34%	-0.4%	-0.21%	0.3%	-0.72%
Net Income (Continuing)	-17M	-21.88M	-26.14M	-30.34M	-50.91M	-33.59M	-47M	-57.04M	-39.7M	-68.13M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.20	-1.43	-1.50	-1.52	-2.35	-1.38	-1.35	-1.64	-1.08	-1.44
EPS Growth %	-0.62%	-0.19%	-0.05%	-0.01%	-0.55%	0.41%	0.02%	-0.21%	0.34%	-0.33%
EPS (Basic)	-1.20	-1.43	-1.50	-1.52	-2.35	-1.38	-1.35	-1.64	-1.08	-1.44
Diluted Shares Outstanding	14.14M	15.28M	17.48M	19.63M	21.63M	24.39M	34.73M	34.85M	36.93M	47.27M
Basic Shares Outstanding	14.14M	15.28M	17.43M	19.62M	21.63M	24.39M	34.73M	34.85M	36.76M	47.27M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	22.95M	26.89M	53.11M	42.65M	46.13M	125.25M	93.06M	52.36M	87.34M	61.47M
Cash & Short-Term Investments	17M	21.06M	47.21M	36.2M	35.09M	119.15M	83.92M	41.39M	75.28M	49.74M
Cash Only	17M	21.06M	47.21M	36.2M	35.09M	119.15M	83.92M	41.39M	75.28M	49.74M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	707.38K	5.21K	844K	997K	1.26M	3.88M	6.93M	2.84M	2.97M	8.54M
Days Sales Outstanding	972.32	1.22	1.22K	3.14K	6.74K	28.32K	955.04	217.2	29.91	-268.35
Inventory	1.21M	-5.03M	-4.9M	1.09M	2.67M	0	-3.04M	2.98M	200K	0
Days Inventory Outstanding	1.23K	-	-	-	-	-	-	1.1K	-	-
Other Current Assets	4.66M	5.02M	4.73M	5.33M	4.43M	0	3.04M	2.17M	6.33M	-1K
Total Non-Current Assets+	3.47M	3.51M	4.36M	3.54M	10.08M	8.78M	8.71M	7.41M	6.56M	5.95M
Property, Plant & Equipment	2.43M	2.43M	2.99M	2.88M	9.39M	8.26M	8.19M	7.12M	6.11M	5.54M
Fixed Asset Turnover	0.11x	0.64x	0.08x	0.04x	0.01x	0.01x	0.32x	0.67x	5.93x	-2.10x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	7.53K	4.45K	135.97K	102K	163K	21K	4K	1K	8K	7K
Long-Term Investments	218.12K	242.22K	272.93K	176K	131K	105K	98K	0	0	0
Other Non-Current Assets	0	0	0	382K	-1K	-1K	421K	291K	443K	406K
Total Assets+	26.42M	30.4M	57.47M	46.2M	56.2M	134.03M	101.77M	59.77M	93.9M	67.42M
Asset Turnover	0.01x	0.05x	0.00x	0.00x	0.00x	0.00x	0.03x	0.08x	0.39x	-0.17x
Asset Growth %	-0.29%	0.15%	0.89%	-0.2%	0.22%	1.38%	-0.24%	-0.41%	0.57%	-0.28%
Total Current Liabilities+	7.1M	8.25M	9.35M	11.6M	14.35M	19.04M	36.84M	37.94M	49.87M	58.94M
Accounts Payable	3.59M	4.37M	5.14M	4.54M	6.15M	5.57M	5M	4M	6.7M	4.48M
Days Payables Outstanding	3.64K	3.66K	5.43K	-	-	-	-	1.48K	-	-
Short-Term Debt	1.07M	1.08M	770K	500K	500K	3.67M	7.08M	3.6M	3.82M	3.66M
Deferred Revenue (Current)	1000K	1000K	1000K	93K	1000K	0	1000K	1000K	0	1000K
Other Current Liabilities	-790.5K	556.3K	807.47K	567K	-6.7M	7.06M	5.39M	7.41M	19.86M	8.27M
Current Ratio	3.23x	3.26x	5.68x	3.68x	3.22x	6.58x	2.53x	1.38x	1.75x	1.04x
Quick Ratio	3.06x	3.87x	6.20x	3.58x	3.03x	6.58x	2.61x	1.30x	1.75x	1.04x
Cash Conversion Cycle	-1.44K	-	-	-	-	-	-	-160.03	-	-
Total Non-Current Liabilities+	3.7M	4.76M	4.19M	20.36M	43.77M	44.52M	38.13M	48.88M	45.87M	74.19M
Long-Term Debt	3.53M	4.58M	3.75M	20.02M	37.62M	39.12M	32.42M	44.04M	41.66M	43.01M
Capital Lease Obligations	0	0	0	0	5.81M	4.99M	5.39M	4.57M	3.88M	2.97M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	173.91K	175.21K	446.27K	334K	332K	414K	318K	270K	325K	28.21M
Total Liabilities	10.81M	13M	13.54M	31.95M	58.11M	63.56M	74.98M	86.81M	95.74M	133.12M
Total Debt+	4.6M	5.67M	4.73M	20.52M	44.53M	48.98M	46.02M	53.17M	50.56M	50.9M
Net Debt	-12.4M	-15.39M	-42.48M	-15.68M	9.43M	-70.17M	-37.9M	11.78M	-24.72M	1.17M
Debt / Equity	0.29x	0.33x	0.11x	1.44x	-	0.70x	1.72x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-288.01x	-213.84x	-233.16x	-35.50x	-9.76x	-109.39x	-78.36x	-8.00x	-3.35x	-8.46x
Total Equity+	15.61M	17.4M	43.92M	14.24M	-1.91M	70.47M	26.79M	-27.05M	-1.84M	-65.7M
Equity Growth %	-0.49%	0.11%	1.52%	-0.68%	-1.13%	37.91%	-0.62%	-2.01%	0.93%	-34.63%
Book Value per Share	1.10	1.14	2.51	0.73	-0.09	2.89	0.77	-0.78	-0.05	-1.39
Total Shareholders' Equity	15.61M	17.4M	43.92M	14.24M	-1.91M	70.47M	26.79M	-27.05M	-1.84M	-65.7M
Common Stock	424.97K	478.96K	589K	589K	672K	1.03M	1.04M	1.05M	1.41M	1.42M
Retained Earnings	-17M	-21.88M	-26.14M	-30.34M	-50.91M	-33.59M	-47M	-57.04M	-39.7M	-68.13M
Treasury Stock	-81.88K	-57.77K	-27K	-124K	-169K	-196K	-202K	-228K	-228K	-228K
Accumulated OCI	-20.36M	-35.44M	-54.28M	-78.68M	-104.64M	-152.51M	-182.82M	-226.58M	-276.07M	-311.51M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-16.82M	-18.28M	-21.03M	-25.98M	-41.17M	-27.54M	-29.87M	-37.1M	-12.48M	-19.55M
Operating CF Margin %	-63.34%	-11.73%	-83.47%	-224.01%	-605.43%	-550.76%	-11.29%	-7.77%	-0.34%	1.68%
Operating CF Growth %	-0.96%	-0.09%	-0.15%	-0.24%	-0.58%	0.33%	-0.08%	-0.24%	0.66%	-0.57%
Net Income	-17M	-21.88M	-26.14M	-30.34M	-50.91M	-33.59M	-47M	-57.04M	-39.7M	-68.13M
Depreciation & Amortization	456.08K	482.79K	403.85K	619K	1.77M	1.75M	1.56M	1.5M	1.51M	1.62M
Stock-Based Compensation	1.29M	1.99M	2.61M	1.87M	4.32M	2.92M	3.2M	3.17M	3.3M	4.3M
Deferred Taxes	0	0	0	0	2.1M	5.64M	152K	0	120K	101K
Other Non-Cash Items	8.56K	-75.17K	430.32K	796K	3.08M	-4.34M	678K	12.96M	12.37M	28.28M
Working Capital Changes	-1.57M	1.2M	1.67M	1.08M	-1.52M	73K	11.54M	2.3M	9.92M	14.28M
Change in Receivables	-78.39K	74.82K	-164.29K	144K	-85K	-51K	62K	-101K	-806K	355K
Change in Inventory	0	0	0	0	-2.06M	995K	281K	-2.91M	0	0
Change in Payables	1.35M	788.69K	785.95K	633K	2.06M	-995K	-281K	2.91M	8.68M	0
Cash from Investing+	-2.21M	-444.99K	-1.46M	71K	-1.46M	-112K	-242K	138K	-349K	-955K
Capital Expenditures	-1.49M	-400.1K	-1.46M	-506K	-1.44M	-107K	-233K	-93K	-328K	-846K
CapEx % of Revenue	5.63%	0.26%	5.81%	4.36%	21.24%	2.14%	0.09%	0.02%	0.01%	-0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	72.95K	-44.88K	-224K	577K	1K	-1K	0	0	-21K	-109K
Cash from Financing+	3.06M	22.9M	48.53M	14.85M	41.49M	111.77M	-5.18M	-5.65M	46.77M	-5.13M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	417K	-1.43M	-3.56M	-223K	-461K	-11.05M	-1.44M	-916K	-9.77M	-980K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-18.32M	-18.68M	-22.5M	-26.49M	-42.61M	-27.64M	-30.11M	-37.2M	-12.81M	-20.4M
FCF Margin %	-68.97%	-11.99%	-89.29%	-228.37%	-626.66%	-552.9%	-11.37%	-7.79%	-0.35%	1.76%
FCF Growth %	-0.92%	-0.02%	-0.2%	-0.18%	-0.61%	0.35%	-0.09%	-0.24%	0.66%	-0.59%
FCF per Share	-1.30	-1.22	-1.29	-1.35	-1.97	-1.13	-0.87	-1.07	-0.35	-0.43
FCF Conversion (FCF/Net Income)	0.99x	0.84x	0.80x	0.87x	0.81x	0.82x	0.64x	0.65x	0.31x	0.29x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-74.04%	-132.57%	-85.27%	-102.8%	-825.6%	-98.08%	-96.66%	-	-	-
Return on Invested Capital (ROIC)	-898.73%	-628.39%	-1099.69%	-	-1153.33%	-698.84%	-	-	-	-
Gross Margin	-35.42%	72%	-37.16%	100%	100%	100%	100%	79.38%	100%	100%
Net Margin	-6403.14%	-1404.31%	-10375.62%	-25772.41%	-74875%	-67246%	-1775.75%	-1194.37%	-109.64%	586.89%
Debt / Equity	0.29x	0.33x	0.11x	1.44x	-	0.70x	1.72x	-	-	-
Interest Coverage	-288.01x	-213.84x	-233.16x	-35.50x	-9.76x	-109.39x	-78.36x	-8.00x	-3.35x	-8.46x
FCF Conversion	0.99x	0.84x	0.80x	0.87x	0.81x	0.82x	0.64x	0.65x	0.31x	0.29x
Revenue Growth	-72.55%	486.76%	-83.83%	-53.96%	-41.38%	-26.47%	5194%	80.43%	658.12%	-132.06%

Revenue by Segment

	2020	2021	2023	2024
Other Sales	-	5K	-	5.92M
Other Sales Growth	-	-	-	-
Services	50K	5K	29.75M	-17.53M
Services Growth	-	-90.00%	594900.00%	-158.94%

Frequently Asked Questions

Growth & Financials

Nanobiotix S.A. (NBTX) reported $47.9M in revenue for fiscal year 2024. This represents a 3424% increase from $1.4M in 2011.

Nanobiotix S.A. (NBTX) saw revenue decline by 132.1% over the past year.

Nanobiotix S.A. (NBTX) reported a net loss of $85.1M for fiscal year 2024.

Dividend & Returns

Nanobiotix S.A. (NBTX) had negative free cash flow of $33.2M in fiscal year 2024, likely due to heavy capital investments.